MYC protein collaborate with BCR/ABL1 to induce blastic transformation, as assessed by the therapeutic efficacy of a silencing combination therapy for MYC and BCR/ABL1 of primary CML cells in SCID mice [37]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.